Tumour microenvironment factors may influence cancer progression and response to tamoxifen (Nolvadex) in patients with estrogen receptor-positive and human epidermal growth factor receptor 2 breast cancer

1. In patients with estrogen receptor (ER)+ and human epidermal growth factor receptor 2 (HER2)- breast cancer, certain tumour microenvironments (TMEs) were associated with improved breast cancer progression and treatment response to tamoxifen (Nolvadex). Evidence Rating Level: 1 (Excellent) The TME of tumour, immune, and stromal cells varies depending on breast cancer estrogen receptor status.…